Taiwan’s downward revision of its growth and export forecasts last month confirms the need to diversify from its main business of exporting manufactured commodities.
The government’s “five plus two” innovative industries plan aims to do just that by restructuring the economy toward higher-value, knowledge-based industries, such as biotech, green energy and defense. It includes upgrades to Taiwan’s system for the protection of intellectual property, including the introduction of a patent linkage system.
“The five plus two industries plan focuses on the transformation of Taiwan’s industrial development,” according to Minister Without Portfolio Kung Ming-hsin (龔明鑫), who is a former deputy minister for the National Development Council.
As an established provider of manufactured goods to the world’s supply chains, Taiwan’s industries have been forced to compete on cost rather than value, Kung says.
That diverts companies away from research and development (R&D) and prevents them from moving up the value chain.
The government’s remedy is to support the building of stronger innovative industries in Taiwan. One main area of focus is the biomedical industry.
The pharmaceutical industry is heavily slanted toward generic manufacturing, which means narrow margins and little economic value domestically.
Transforming it into a sector built on innovation rather than copying requires partnership and collaboration with foreign companies. However, investment remains elusive.
Intellectual property is a major roadblock. In its latest research report on Taiwan, IHS Markit said that “challenges in intellectual property rights policies persist, deterring multinational companies from investing in the sector... One major issue is that many patent-infringing drugs are being approved and included in the reimbursement list” of the public health system.
Encouragingly, the administration of President Tsai Ing-wen (蔡英文) recognizes that a system where the national drug regulator approves and the public health system reimburses patent-infringing drugs is incompatible with Taiwan’s ambition to become an innovation-driven economy.
So, Taiwan is one of several countries preparing to introduce a “patent linkage” system to reduce the numbers of generic drugs gaining market approval before the originator patent has expired.
The plan, an amendment to the Pharmaceutical Affairs Act (藥事法) would require the Food and Drug Administration to notify originators when competitors request market approval for a generic version of a patented drug.
Patent linkage is a mechanism for the early resolution of patent disputes, which injects certainty and transparency into the intellectual property (IP) framework.
Generic drug manufacturers would also benefit by receiving the necessary information to contest the validity of questionable originator patents. They would be able to more rapidly launch generic drugs that do not carry a litigation risk.
Greater certainty over IP rights through the proposed patent-linkage system would embolden potential investors in Taiwan, particularly in the innovative life science industry. Greater investment and partnership by these companies would drive innovation. Economic growth and value-added jobs would follow.
Despite the government’s ambitious plans, problems are emerging. Original plans for the patent-linkage scheme covered normal “chemical” pharmaceuticals and newer high-technology “biologic” drugs. Local pharmaceutical companies want biologic drugs excluded from the final law.
That would be a mistake. Biologic drugs — medicines produced from or containing living organisms — are an increasingly important component of the clinical toolkit. They are responsible for startling advances in the treatment of cancer, arthritis and many other diseases.
However, biologics are expensive to produce, with a large-scale biotech facility costing up to five times more than a standard medicine factory. R&D is costlier still. Why risk such a sizeable investment in Taiwan if a company’s IP is not fully protected?
There are fears that the inclusion of biologics in the patent-linkage law would disadvantage the burgeoning Taiwanese biosimilar industry, which manufactures similar versions of original biologic drugs. It is also a strategic sector the government hopes to develop.
The South Korean experience suggests such fears are unfounded. It has a patent-linkage system covering biologics, yet manufactures two in three biosimilars sold worldwide, according to Business Korea.
South Korea’s exports of biosimilars grew by 29 percent in 2017 to US$1.37 billion, accounting for 34 percent of its total pharmaceutical exports.
This suggests a thriving biosimilars industry could emerge within a strong IP framework, and patent linkage is no threat.
A robust IP rights framework is essential for achieving the government’s ambition of moving to a high-value, knowledge-based economy. Within that, a broad patent-linkage system would put Taiwan’s IP system in line with the world’s most competitive knowledge economies, including the US, South Korea and Singapore. The new reform should be welcomed.
Philip Stevens is executive director of Geneva Network, a UK-based research organization focusing on international innovation and trade policy.
There are moments in history when America has turned its back on its principles and withdrawn from past commitments in service of higher goals. For example, US-Soviet Cold War competition compelled America to make a range of deals with unsavory and undemocratic figures across Latin America and Africa in service of geostrategic aims. The United States overlooked mass atrocities against the Bengali population in modern-day Bangladesh in the early 1970s in service of its tilt toward Pakistan, a relationship the Nixon administration deemed critical to its larger aims in developing relations with China. Then, of course, America switched diplomatic recognition
The international women’s soccer match between Taiwan and New Zealand at the Kaohsiung Nanzih Football Stadium, scheduled for Tuesday last week, was canceled at the last minute amid safety concerns over poor field conditions raised by the visiting team. The Football Ferns, as New Zealand’s women’s soccer team are known, had arrived in Taiwan one week earlier to prepare and soon raised their concerns. Efforts were made to improve the field, but the replacement patches of grass could not grow fast enough. The Football Ferns canceled the closed-door training match and then days later, the main event against Team Taiwan. The safety
The National Immigration Agency on Tuesday said it had notified some naturalized citizens from China that they still had to renounce their People’s Republic of China (PRC) citizenship. They must provide proof that they have canceled their household registration in China within three months of the receipt of the notice. If they do not, the agency said it would cancel their household registration in Taiwan. Chinese are required to give up their PRC citizenship and household registration to become Republic of China (ROC) nationals, Mainland Affairs Council Minister Chiu Chui-cheng (邱垂正) said. He was referring to Article 9-1 of the Act
Strategic thinker Carl von Clausewitz has said that “war is politics by other means,” while investment guru Warren Buffett has said that “tariffs are an act of war.” Both aphorisms apply to China, which has long been engaged in a multifront political, economic and informational war against the US and the rest of the West. Kinetically also, China has launched the early stages of actual global conflict with its threats and aggressive moves against Taiwan, the Philippines and Japan, and its support for North Korea’s reckless actions against South Korea that could reignite the Korean War. Former US presidents Barack Obama
RSS